Company News: Jomaa Pharma and Medicines for Malaria Venture to Co-develop Novel Malaria Treatment Based on Fosmidomycin
– New treatment options for drug-resistant malaria types –
Jomaa Pharma GmbH, a German biopharmaceutical company engaged in malaria chemotherapy, and Medicines for Malaria Venture (MMV), a not-for-profit research foundation, announced today that they have signed a Memorandum of Understanding for the joint development of fosmidomycin, as a component of non-artemisinin based combination therapy (NACT), for acute Plasmodium falciparum malaria. Fosmidomycin is a molecule that possesses antimalarial and antibacterial activity. The stimulus for this co-development project follows reports of the emergence of artemisinin resistance on the Thai-Cambodian border.
The prospect of overcoming this drug-resistance through fosmidomycin when combined with piperaquine is considered to be very promising and constitutes the basis of the partnership between Jomaa Pharma and MMV.